The Global Human Insulin Market Report is equipped with market data from 2014 to 2024. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2019 to 2024. The detailed sales channel is also covered in the study.
Human insulin is the name which describes synthetic insulin which is laboratory grown to mimic the insulin in humans.
Scope of the Report:
In 2018, North America is estimated to dominate the global human insulin market. The Asia-Pacific market is poised to grow the fastest, during the forecast period, owing to growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, continued expansion of advanced medical facilities in emerging countries (such as China & India), and rising public awareness related to benefits offered by human insulin in diabetes treatment.
The worldwide market for Human Insulin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019.
This report focuses on the Human Insulin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- B. Braun
- Becton, Dickinson
- Biocon
- Biodel
- ELI Lilly
- Julphar
- NOVO Nordisk
- Sanofi
- Wockhardt
- Ypsomed
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Insulin Analogs and Biosimilars
- Human Insulin Biologics
Market Segment by Applications, can be divided into
- Short acting
- Intermediate acting
- Long acting
- Pre-mix Insulin
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Insulin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Human Insulin, with price, sales, revenue and global market share of Human Insulin in 2017 and 2018.
Chapter 3, the Human Insulin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Insulin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Human Insulin market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Human Insulin sales channel, distributors, customers, research findings and conclusion, appendix and data source.